Importantly, the IDO antagonist 1-methyl-d,l-tryptophan is able to block LPS-induced depression-like behavior, while the levels of proinflammatory cytokines and sickness behavior remain unchanged (191). Here, IDO1 is linked to depressive symptom measurement.